SG11202111533XA - Anti-proliferative agents for treating pah - Google Patents

Anti-proliferative agents for treating pah

Info

Publication number
SG11202111533XA
SG11202111533XA SG11202111533XA SG11202111533XA SG11202111533XA SG 11202111533X A SG11202111533X A SG 11202111533XA SG 11202111533X A SG11202111533X A SG 11202111533XA SG 11202111533X A SG11202111533X A SG 11202111533XA SG 11202111533X A SG11202111533X A SG 11202111533XA
Authority
SG
Singapore
Prior art keywords
proliferative agents
treating pah
pah
treating
proliferative
Prior art date
Application number
SG11202111533XA
Inventor
Samit Kumar Bhattacharya
Douglas Carl Behenna
Kimberly O Cameron
Ping Chen
John M Curto
Kevin Daniel Freeman-Cook
Mehran Jalaie
Robert Steven Kania
Yajing Lian
Sajiv Krishnan Nair
Cynthia Louise Palmer
Martin Youngjin Pettersson
Eugene Yuanjin Rui
Matthew Forrest Sammons
Qingyi Yang
Liying Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11202111533XA publication Critical patent/SG11202111533XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
SG11202111533XA 2019-04-19 2020-04-15 Anti-proliferative agents for treating pah SG11202111533XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836340P 2019-04-19 2019-04-19
US202062981620P 2020-02-26 2020-02-26
PCT/IB2020/053550 WO2020212865A1 (en) 2019-04-19 2020-04-15 Anti-proliferative agents for treating pah

Publications (1)

Publication Number Publication Date
SG11202111533XA true SG11202111533XA (en) 2021-11-29

Family

ID=70465141

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111533XA SG11202111533XA (en) 2019-04-19 2020-04-15 Anti-proliferative agents for treating pah

Country Status (15)

Country Link
US (1) US11203594B2 (en)
EP (1) EP3956031A1 (en)
JP (1) JP2022529930A (en)
KR (1) KR20220003565A (en)
CN (1) CN114007697A (en)
AU (1) AU2020260018A1 (en)
BR (1) BR112021020295A2 (en)
CA (1) CA3136880C (en)
IL (1) IL287374A (en)
MX (1) MX2021012491A (en)
SG (1) SG11202111533XA (en)
TW (1) TWI744866B (en)
UY (1) UY38665A (en)
WO (1) WO2020212865A1 (en)
ZA (1) ZA202107695B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515629A (en) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Compounds as CDK2/4/6 inhibitors
CN113125602A (en) * 2021-04-16 2021-07-16 山东铂源药业有限公司 Method for detecting residual solvent in thujaplicin
CN114773391A (en) * 2022-03-24 2022-07-22 联碳新材料技术(杭州)有限公司 Fluorine-containing transition metal complex, preparation method and application thereof
CN114751884A (en) * 2022-05-06 2022-07-15 河南应用技术职业学院 Synthetic method of (3S,4R) -4-amino oxacyclohex-3-ol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (en) 1984-10-23 1986-04-30 Rentschler Arzneimittel PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF
KR0182801B1 (en) 1991-04-16 1999-05-01 아만 히데아키 Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (en) 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
DE19504832A1 (en) 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
ES2287971T3 (en) 1997-08-11 2007-12-16 Pfizer Products Inc. SOLID PHARMACEUTICAL DISPERSIONS WITH INCREASED BIODISPONIBILITY.
JP2008510770A (en) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pteridinone as a PLK inhibitor
US9815834B2 (en) * 2014-02-07 2017-11-14 Principia Biopharma, Inc. Quinolone derivatives as fibroblast growth factor receptor inhibitors
UA124804C2 (en) * 2016-08-15 2021-11-24 Пфайзер Інк. Pyridopyrimdinone cdk2/4/6 inhibitors
KR20190071763A (en) * 2016-10-20 2019-06-24 화이자 인코포레이티드 Antiproliferative agents for the treatment of pulmonary arterial hypertension

Also Published As

Publication number Publication date
CA3136880A1 (en) 2020-10-22
EP3956031A1 (en) 2022-02-23
JP2022529930A (en) 2022-06-27
IL287374A (en) 2021-12-01
KR20220003565A (en) 2022-01-10
BR112021020295A2 (en) 2021-12-14
TWI744866B (en) 2021-11-01
ZA202107695B (en) 2023-04-26
MX2021012491A (en) 2022-01-24
UY38665A (en) 2020-11-30
TW202104224A (en) 2021-02-01
US11203594B2 (en) 2021-12-21
AU2020260018A1 (en) 2021-11-04
CN114007697A (en) 2022-02-01
WO2020212865A1 (en) 2020-10-22
US20200331909A1 (en) 2020-10-22
CA3136880C (en) 2023-09-19

Similar Documents

Publication Publication Date Title
IL285496A (en) Methods for treating cholestasis
IL287374A (en) Anti-proliferative agents for treating pah
GB2573161B (en) Floor treatment machine
IL288201A (en) Apparatus for treating teeth
PL3784103T3 (en) Floor treatment machine
ZA201907973B (en) Agent for preventing or treating brain atrophy
IL288937A (en) Improved treatment using eyp001
IL266026A (en) Anti-proliferative agents for treating pah
EP4001364A4 (en) Surface treatment agent
PL4080313T3 (en) Treatment system for treating workpieces
GB201914296D0 (en) Treatment
GB201911417D0 (en) Floor treatment machine
IL284668A (en) Methods for treating schizophrenia
GB201907065D0 (en) Surface treatment method
GB201919208D0 (en) Treatment apparatus
HUE064641T2 (en) Waste treatment apparatus
EP4098263A4 (en) Treatment for chondrodystrophia
GB201912760D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201911603D0 (en) Treatment
GB201910755D0 (en) Treatment
GB201904253D0 (en) Treatment
EP4051214A4 (en) Method for treating skin